TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 160846

Group type: EXPERIMENTAL
Intervention: Ipratropium (80 micrograms applied intranasally 4 times a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 20
Study: 31161947

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 80
Study: 28786993

Group type: EXPERIMENTAL
Intervention: Uric acid administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rasburicase administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 20
Study: 26536700

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of parecoxib sodium 40 mg after surgery, continued with 40 mg injections after 12, 24, and 36 hours.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 100 mg tramadol after surgery, replacing parecoxib sodium in group C.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Blank control group without any analgesia measures.
Number of subjects: 90
Study: 22859618

Group type: EXPERIMENTAL
Intervention: Red wine (450 ml daily for 4 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: De‐alcoholized red wine (450 ml daily for 4 weeks)
Number of subjects: 19
Study: 21592388

Group type: EXPERIMENTAL
Intervention: Early STOPP intervention delivered by a trained coach (dietitian, physiotherapist or a nurse) focusing on healthy food choices, increasing physical activity, reducing sedentary behavior, and regulating sleeping patterns.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study: 19191781

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Every 3 weeks paclitaxel treatment
Number of subjects: 47
Study: 16790607

Group type: EXPERIMENTAL
Intervention: 50:50 mixture of nitrous oxide/oxygen (N2O/O2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Air
Number of subjects: 90
Study: 12765500

Group type: EXPERIMENTAL
Intervention: Individual, standardised debriefing session based on critical incident stress debriefing principles within 72 hours of delivery
Number of subjects: 1745

Group type: COMPARATOR
Intervention: Control group (no debriefing)
Number of subjects: 1745

Group type: EXPERIMENTAL
Intervention: Individual, standardised debriefing session
Number of subjects: 1745
Study: 10857142

Group type: EXPERIMENTAL
Intervention: Terazosin (5 mg per day in single dose)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Alfuzosin (7.5 mg per day in 3 doses)
Number of subjects: 74
Study: 9358213

Group type: EXPERIMENTAL
Intervention: 5-FU monotherapy (600 mg/m2)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Combination of 5-FU (600 or 400 mg/m2) and high-dose FA (400 mg/m2)
Number of subjects: 49
Study: 8257226

Group type: EXPERIMENTAL
Intervention: Neostigmine (0.5 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Glucagon (1 unit)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Meal
Number of subjects: 23
Study: 4037436

Group type: EXPERIMENTAL
Intervention: Dust control measures alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dust control measures combined with electrostatic and high efficiency particulate air filters
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31430286

Group type: EXPERIMENTAL
Intervention: Health System Strengthening (HSS) intervention
Number of subjects: 1514

Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 1514
Study: 29528768

Group type: EXPERIMENTAL
Intervention: Low-glycemic-index diet rich in multiple functional foods (LE + FF)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low-glycemic-index diet (LE)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Isocaloric control diet
Number of subjects: 90
Study: 25403253

Group type: EXPERIMENTAL
Intervention: Kinesiological taping
Number of subjects: 70

Group type: COMPARATOR
Intervention: Subacromial injection therapy (Betamethasone plus prilocaine)
Number of subjects: 70
Study: 25202858

Group type: EXPERIMENTAL
Intervention: Prophylactic administration of fresh frozen plasma (FFP)
Number of subjects: 55
Study: 23131815

Group type: EXPERIMENTAL
Intervention: High dietary social support
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Life dissatisfaction
Number of subjects: 178
Study: 19384779

Group type: EXPERIMENTAL
Intervention: IOL optic captured behind the posterior capsule with posterior capsulotomy (group 1)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: IOL optic implanted in the bag with posterior capsulotomy (group 2)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: IOL optic implanted in the bag without posterior capsulotomy (group 3)
Number of subjects: 73
Study: 17718367

Group type: EXPERIMENTAL
Intervention: Visual components (Lv)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual components (Sv)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditory components (La)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditory components (Sa)
Number of subjects: 0
Study: 15279342

Group type: EXPERIMENTAL
Intervention: Lactose-free formula (Dumex Lactose-Free Formula)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lactose-containing formula (Dumex Infant Formula)
Number of subjects: 80
Study: 12148300

Group type: EXPERIMENTAL
Intervention: Bupivacain 0.5% (4 ml) injected retrobulbarly before surgery (group I)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bupivacain 0.5% (4 ml) injected retrobulbarly after surgery (group II)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No retrobulbar anesthesia (group III)
Number of subjects: 45
Study: 9586589

Group type: EXPERIMENTAL
Intervention: Medical therapy with selective, long‐acting, alpha1‐blocking agents (terazosin, doxazosin, tamsulosin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finasteride (5‐alpha‐reductase inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Device therapies (Laser prostatectomy including VLAP, TUEP, TILP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical and device therapies
Number of subjects: 0
Study: 7862899

Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 ml/kg body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol treatments
Number of subjects: 0
Study: 2536911

Group type: COMPARATOR
Intervention: MAC chemotherapy (methotrexate, dactinomycin, and chlorambucil)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: modified CHAMOMA regimen (methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine)
Number of subjects: 42
Study: 259

Group type: EXPERIMENTAL
Intervention: Metal cannula
Number of subjects: 150

Group type: COMPARATOR
Intervention: Plastic cannula
Number of subjects: 150
Study: 31977104

Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Letter intervention
Number of subjects: 1003

Group type: COMPARATOR
Intervention: No-contact control condition
Number of subjects: 1003
Study: 30535516

Group type: EXPERIMENTAL
Intervention: NIV after early extubation
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard extubation
Number of subjects: 130
Study: 28958137

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Temperature controlled High Energy Adjustable multi-mode emission Laser (THEAL)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Stretching exercises
Number of subjects: 45
Study: 25590507

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide
Number of subjects: 37
Study: 23235439

Group type: EXPERIMENTAL
Intervention: Early surgery group (ES)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Comparison of CDGAS differences between ES and CO
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 54
Study: 21553981

Group type: EXPERIMENTAL
Intervention: Implementation intention formation
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 227
Study: 17947605

Group type: EXPERIMENTAL
Intervention: Enteral formula containing 50 g of saccharides enriched with 2.3 g of fiber/100 mL
Number of subjects: 10

Group type: COMPARATOR
Intervention: Enteral formula containing 50 g of saccharides
Number of subjects: 10
Study: 15618070

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 1749

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1749
Study: 12131722

Group type: EXPERIMENTAL
Intervention: Interventional open MRI
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control subjects with no history of low back pain
Number of subjects: 29
Study: 9621141

Group type: EXPERIMENTAL
Intervention: Recombinant IFN-beta (0.15 x 10(6) IU/g) applied 5 times daily for 4 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Recombinant IFN-beta (1.0 x 10(6) IU/g) applied 5 times daily for 4 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo gel applied 5 times daily for 4 weeks
Number of subjects: 120
Study: 7633951

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon-alpha cream (2 x 10(6) IU/g) applied three times daily for 5 consecutive days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo cream applied three times daily for 5 consecutive days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon-alpha cream
Number of subjects: 60
Study: 2752873

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study: 330080

Group type: EXPERIMENTAL
Intervention: Sulindac given twice daily (100 to 300 mg daily, adjusted according to patient response)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Sulindac given 4 times daily (100 to 300 mg daily, adjusted according to patient response)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 31609870

Group type: EXPERIMENTAL
Intervention: Caregiver-delivered foot reflexology for patients (15 days, once a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (reading session)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Caregiver-delivered foot reflexology and control group (reading session)
Number of subjects: 60
Study: 28556581

Group type: EXPERIMENTAL
Intervention: Selexipag (Uptravi)
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Selexipag (Uptravi) with PAH comedication
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1156
Study: 26321524

Group type: EXPERIMENTAL
Intervention: Yupingfeng granules, 10 g/time, tid for 2 courses
Number of subjects: 58

Group type: COMPARATOR
Intervention: Synchronous radiotherapy and chemotherapy (Control)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Yupingfeng granules
Number of subjects: 58
Study: 23301779

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise (4 sets, 8-10 repetitions/set, 65-70% 1RM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (4 sets, 4-6 repetitions/set, 85-90% 1RM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study: 21519814

Group type: EXPERIMENTAL
Intervention: 4-week schedule of gemcitabine (1000 mg/m² as a 30-min infusion weekly for 3 consecutive weeks every 4 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 3-week schedule of gemcitabine (1000 mg/m² as a 30-min infusion weekly for 2 consecutive weeks every 3 weeks)
Number of subjects: 90
Study: 18821031

Group type: EXPERIMENTAL
Intervention: Use of patient-reported outcomes (PROs) in clinical practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional individual patient trials
Number of subjects: 0
Study: 16549639

Group type: EXPERIMENTAL
Intervention: Total homocysteine (tHcy) measured in tertiles (<14.7, 14.7 to 19.5, > or =19.6 micromol/L)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Total homocysteine (tHcy) adjusted for GFR
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Total homocysteine (tHcy) as a continuous variable
Number of subjects: 840
Study: 15354908

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer/fluoride liquid dentifrice
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fluoride-containing traditional control toothpaste
Number of subjects: 19
Study: 12131319

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin substitution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (nonwarfarin treated patients)
Number of subjects: 20
Study: 9817273

Group type: EXPERIMENTAL
Intervention: 500 mg/m2 amifostine intravenously before HD-RIT
Number of subjects: 50

Group type: COMPARATOR
Intervention: Physiologic saline solution (Control)
Number of subjects: 50
Study: 7656141

Group type: EXPERIMENTAL
Intervention: High humidity environment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal humidity environment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isotonic saline (0.9%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (1.5%)
Number of subjects: 10
Study: 2468978

Group type: EXPERIMENTAL
Intervention: 10% pentastarch (group P)
Number of subjects: 94

Group type: COMPARATOR
Intervention: 5% albumin (group A)
Number of subjects: 94
Study: 330440

Group type: EXPERIMENTAL
Intervention: Lofepramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 0
Study: 31151486

Group type: EXPERIMENTAL
Intervention: Preoperative immunonutrition
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (historical)
Number of subjects: 96
Study: 28079825

Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg/kg administered at loss of eyelash reflex (Control group C; n=45)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg administered when BIS fell to less than 40 (Experimental group T; n=45)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg administered when BIS fell below 40 after manual ventilation with sevoflurane (Experimental group S; n=45)
Number of subjects: 135
Study: 25014236

Group type: EXPERIMENTAL
Intervention: Digestive Symptom Frequency Questionnaire (DSFQ)
Number of subjects: 200
Study: 24002321

Group type: EXPERIMENTAL
Intervention: Neuropsychological intervention (supportive and psycho-educational sessions with a neuropsychologist)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 86
Study: 21819167

Group type: EXPERIMENTAL
Intervention: Multimodal hypertension intervention
Number of subjects: 283

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 283
Study: 19414236

Group type: EXPERIMENTAL
Intervention: Positively enhanced dosed exposure (PDE)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Dosed-only exposure (DE)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Prolonged exposure (PE)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Negatively-supplemented dosed exposure (NDE)
Number of subjects: 39
Study: 17548726

Group type: EXPERIMENTAL
Intervention: Aerobic interval training (95% of peak heart rate) 3 times per week for 12 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Moderate continuous training (70% of highest measured heart rate) 3 times per week for 12 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (standard advice regarding physical activity)
Number of subjects: 27
Study: 14627997

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11685593

Group type: EXPERIMENTAL
Intervention: 7 days' intravenous antibiotics (group A)
Number of subjects: 92

Group type: COMPARATOR
Intervention: 3 days' intravenous antibiotics (group B)
Number of subjects: 92
Study: 9457458

Group type: EXPERIMENTAL
Intervention: Carteolol 2% and pilocarpine 2% (CBS341A)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Timolol 0.5% and pilocarpine 2%
Number of subjects: 209
Study: 8186347

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg/day for 3 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-drug control period
Number of subjects: 24
Study: 3369330

Group type: EXPERIMENTAL
Intervention: Placebo injections with strict surveillance of alcohol intake
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Placebo injections without surveillance
Number of subjects: 70

Group type: COMPARATOR
Intervention: No placebo injections with surveillance
Number of subjects: 70

Group type: COMPARATOR
Intervention: No placebo injections without surveillance
Number of subjects: 70
Study: 30550515

Group type: EXPERIMENTAL
Intervention: RERmax ≥1.10
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: HRmax ≥95% of age‐predicted HRmax
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: RPEmax ≥19
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: BLmax ≥8 mmol·L
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Intraclass correlation for RERmax
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Intraclass correlation for HRmax
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Intraclass correlation for BLmax
Number of subjects: 83
Study: 30052722

Group type: EXPERIMENTAL
Intervention: Intervention group (HIV prevention intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no direct intervention)
Number of subjects: 0
Study: 26348533

Group type: EXPERIMENTAL
Intervention: Intravenous administration of olodaterol (0.5-25 μg)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Oral inhalation of olodaterol (2.5-70 μg via Respimat® inhaler)
Number of subjects: 148
Study: 25292398

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication treatment
Number of subjects: 86
Study: 22452975

Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen during pulmonary rehabilitation (PR)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Room air during pulmonary rehabilitation (PR)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen during PR
Number of subjects: 51

Group type: COMPARATOR
Intervention: Room air during PR
Number of subjects: 51
Study: 20943455

Group type: EXPERIMENTAL
Intervention: Intermittent Pringle maneuver and ischemic preconditioning followed by continuous Pringle maneuver
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent Pringle maneuver
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemihepatic vascular occlusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total hepatic vascular exclusion (THVE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective hepatic vascular exclusion (SHVE)
Number of subjects: 0
Study: 17981449

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1.84 g/day of EPA and DHA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (corn oil with 1% fish oil)
Number of subjects: 59
Study: 16439505

Group type: EXPERIMENTAL
Intervention: Auto-crosslinked hyaluronan gel
Number of subjects: 52

Group type: COMPARATOR
Intervention: No adhesion prevention (Control)
Number of subjects: 52
Study: 11880820

Group type: EXPERIMENTAL
Intervention: Mechanical Optimal Cadence (MOC, 90 rpm)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Freely Chosen Cadence (FCC, 81.2 +/- 7.2 rpm)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Energetically Optimal Cadence (EOC, 72.5 +/- 4.6 rpm)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isolated Run (IR)
Number of subjects: 8
Study: 9446844

Group type: EXPERIMENTAL
Intervention: Pregnant women consuming 450 microg folate/d
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pregnant women consuming 850 microg folate/d
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonpregnant controls
Number of subjects: 24
Study: 8556899

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Supplementation with psychosocial stimulation
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 2118417

Group type: EXPERIMENTAL
Intervention: Leuprolide and flutamide
Number of subjects: 603

Group type: COMPARATOR
Intervention: Leuprolide alone
Number of subjects: 603
Study: 727887

Group type: EXPERIMENTAL
Intervention: Methadyl acetate
Number of subjects: 636

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 636
Study: 30779529

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Axitinib
Number of subjects: 861

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 861
Study: 28965868

Group type: EXPERIMENTAL
Intervention: Healthy food consumption education and discount coupons for healthy food
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 25869827

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Psychoanalytic psychotherapy (PPT)
Number of subjects: 68
Study: 25547983

Group type: EXPERIMENTAL
Intervention: Autologous platelet rich plasma (PRP) treatment
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard moist wound care (Control)
Number of subjects: 150
Study: 22482969

Group type: EXPERIMENTAL
Intervention: Nerve-sparing radical hysterectomy (NRH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional radical hysterectomy (RH)
Number of subjects: 30
Study: 20093333

Group type: EXPERIMENTAL
Intervention: Classic ECC (open modification)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Mini-ECC
Number of subjects: 54
Study: 18416281

Group type: EXPERIMENTAL
Intervention: Levetiracetam (250, 500, or 1000 mg, single dose) after acetylsalicylic acid (aspirin)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Levetiracetam (twice daily for 4 days) with aspirin administered with the penultimate dose
Number of subjects: 6

Group type: COMPARATOR
Intervention: Levetiracetam (twice daily for 4.5 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (twice daily for 4.5 days)
Number of subjects: 6
Study: 15903357

Group type: EXPERIMENTAL
Intervention: Newly designed physical training program (EG)
Number of subjects: 1967

Group type: COMPARATOR
Intervention: Traditional Basic Combat Training physical training program (CG)
Number of subjects: 1967